Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$297.45	$310.76	$284.19 ▼ $495.55	$39.71B	0.31	1.08 million shs	681,280 shs
BIIB Biogen	$193.76	$185.66	$121.05 ▼ $205.97	$28.61B	0.19	1.21 million shs	892,915 shs
REGN Regeneron Pharmaceuticals	$638.88	$729.30	$476.49 ▼ $821.11	$67.54B	0.3	1.01 million shs	994,824 shs
VRTX Vertex Pharmaceuticals	$434.52	$440.68	$362.50 ▼ $507.92	$110.28B	0.3	1.23 million shs	1.75 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+3.91%	-2.65%	-10.64%	+2.58%
BIIB Biogen	0.00%	+0.96%	+5.09%	-0.70%	+54.01%
REGN Regeneron Pharmaceuticals	0.00%	+1.46%	-14.99%	-17.26%	+8.59%
VRTX Vertex Pharmaceuticals	0.00%	-0.47%	+0.95%	-10.85%	-0.34%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$297.45	$310.76	$284.19 ▼ $495.55	$39.71B	0.31	1.08 million shs	681,280 shs
BIIB Biogen	$193.76	$185.66	$121.05 ▼ $205.97	$28.61B	0.19	1.21 million shs	892,915 shs
REGN Regeneron Pharmaceuticals	$638.88	$729.30	$476.49 ▼ $821.11	$67.54B	0.3	1.01 million shs	994,824 shs
VRTX Vertex Pharmaceuticals	$434.52	$440.68	$362.50 ▼ $507.92	$110.28B	0.3	1.23 million shs	1.75 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	0.00%	+3.91%	-2.65%	-10.64%	+2.58%
BIIB Biogen	0.00%	+0.96%	+5.09%	-0.70%	+54.01%
REGN Regeneron Pharmaceuticals	0.00%	+1.46%	-14.99%	-17.26%	+8.59%
VRTX Vertex Pharmaceuticals	0.00%	-0.47%	+0.95%	-10.85%	-0.34%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.85	Moderate Buy	$463.13	55.70% Upside
BIIB Biogen	2.52	Moderate Buy	$215.62	11.28% Upside
REGN Regeneron Pharmaceuticals	2.70	Moderate Buy	$792.65	24.07% Upside
VRTX Vertex Pharmaceuticals	2.92	Moderate Buy	$555.17	27.77% Upside

Current Analyst Ratings Breakdown

Latest ALNY, VRTX, REGN, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$380.00
5/19/2026	REGN Regeneron Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$1,057.00 ➝ $875.00
5/18/2026	VRTX Vertex Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
5/18/2026	ALNY Alnylam Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
5/18/2026	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$900.00 ➝ $730.00
5/18/2026	REGN Regeneron Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$796.00 ➝ $778.00
5/18/2026	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$950.00 ➝ $850.00
5/18/2026	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$762.00 ➝ $707.00
5/18/2026	REGN Regeneron Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$800.00 ➝ $700.00
5/18/2026	REGN Regeneron Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$875.00 ➝ $855.00
5/18/2026	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$900.00 ➝ $700.00

(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	10.69	$2.80 per share	106.38	$8.05 per share	36.95
BIIB Biogen	$9.89B	2.89	$22.64 per share	8.56	$126.33 per share	1.53
REGN Regeneron Pharmaceuticals	$14.34B	4.71	$41.98 per share	15.22	$297.23 per share	2.15
VRTX Vertex Pharmaceuticals	$12.00B	9.19	$17.58 per share	24.72	$76.29 per share	5.70

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$3.66	81.27	28.96	N/A	11.72%	85.76%	10.32%	7/30/2026 (Estimated)
BIIB Biogen	$1.29B	$9.32	20.79	11.70	1.71	13.81%	12.83%	8.01%	7/30/2026 (Estimated)
REGN Regeneron Pharmaceuticals	$4.50B	$41.04	15.57	15.37	1.41	29.65%	13.16%	10.17%	7/30/2026 (Estimated)
VRTX Vertex Pharmaceuticals	$3.95B	$16.86	25.77	22.85	1.86	35.51%	23.86%	17.13%	8/3/2026 (Estimated)

Latest ALNY, VRTX, REGN, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/4/2026	Q1 2026	VRTX Vertex Pharmaceuticals	$4.24	$4.47	+$0.23	$4.02	$2.99 billion	$2.99 billion
4/30/2026	Q1 2026	ALNY Alnylam Pharmaceuticals	$0.8720	$1.99	+$1.1180	$1.51	$1.12 billion	$1.17 billion
4/29/2026	Q1 2026	BIIB Biogen	$2.95	$3.57	+$0.62	$2.15	$2.29 billion	$2.48 billion
4/29/2026	Q1 2026	REGN Regeneron Pharmaceuticals	$8.91	$9.47	+$0.56	$6.75	$3.48 billion	$3.61 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	$3.76	0.59%	N/A	9.16%	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest ALNY, VRTX, REGN, and BIIB Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/29/2026	REGN Regeneron Pharmaceuticals	quarterly	$0.94	0.58%	5/20/2026	5/20/2026	6/4/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.94	3.13	3.06
BIIB Biogen	0.34	3.06	2.41
REGN Regeneron Pharmaceuticals	0.06	3.57	2.96
VRTX Vertex Pharmaceuticals	N/A	3.02	2.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
BIIB Biogen	87.93%
REGN Regeneron Pharmaceuticals	83.31%
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
BIIB Biogen	0.25%
REGN Regeneron Pharmaceuticals	6.97%
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.51 million	132.37 million	Optionable
BIIB Biogen	7,500	147.64 million	147.27 million	Optionable
REGN Regeneron Pharmaceuticals	15,410	105.72 million	98.35 million	Optionable
VRTX Vertex Pharmaceuticals	6,400	253.80 million	253.30 million	Optionable

ALNY, VRTX, REGN, and BIIB Headlines

Recent News About These Companies

Biotech Stocks To Watch Now - May 25th

32 minutes ago | americanbankingnews.com

Legal & General Group Plc Acquires 17,808 Shares of Vertex Pharmaceuticals Incorporated $VRTX

May 25 at 6:35 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Intermede Investment Partners Ltd

May 25 at 6:00 AM | marketbeat.com

Simplify Asset Management Inc. Acquires 16,267 Shares of Vertex Pharmaceuticals Incorporated $VRTX

May 25 at 5:50 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Acquired by Jefferies Financial Group Inc.

May 25 at 5:39 AM | marketbeat.com

Biotech Stocks To Research - May 24th

May 25 at 5:03 AM | americanbankingnews.com

Swedbank AB Raises Position in Vertex Pharmaceuticals Incorporated $VRTX

May 24 at 7:01 AM | marketbeat.com

366,854 Shares in Vertex Pharmaceuticals Incorporated $VRTX Purchased by Life Cycle Investment Partners Ltd

May 24 at 6:09 AM | marketbeat.com

HighTower Advisors LLC Buys 3,544 Shares of Vertex Pharmaceuticals Incorporated $VRTX

May 24 at 4:49 AM | marketbeat.com

Northwestern Mutual Wealth Management Co. Has $7.46 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

May 23 at 4:51 AM | marketbeat.com

Americana Partners LLC Acquires 2,665 Shares of Vertex Pharmaceuticals Incorporated $VRTX

May 23 at 3:26 AM | marketbeat.com

Gabelli Funds LLC Trims Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX

May 22, 2026 | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by ABN Amro Investment Solutions

May 22, 2026 | marketbeat.com

Polycystic Kidney Disease Market Analysis Report 2026-2036, Profiles of Key Players - Otsuka Pharmaceutical, Novartis, Pfizer, and Vertex Pharmaceuticals

May 21, 2026 | finance.yahoo.com

Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults

May 21, 2026 | finance.yahoo.com

What Are Wall Street Analysts' Target Price for Vertex Pharmaceuticals Stock?

May 21, 2026 | barchart.com

Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness

May 21, 2026 | finance.yahoo.com

Leonteq Securities AG Takes Position in Vertex Pharmaceuticals Incorporated $VRTX

May 21, 2026 | marketbeat.com

31,281 Shares in Vertex Pharmaceuticals Incorporated $VRTX Bought by Fideuram Intesa Sanpaolo Private Banking S.P.A.

May 20, 2026 | marketbeat.com

Vertex Pharmaceuticals Incorporated $VRTX Stake Raised by Atle Fund Management AB

May 20, 2026 | marketbeat.com

Vertex Pharmaceuticals Incorporated (VRTX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

May 19, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ALNY, VRTX, REGN, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$297.45 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$298.91 +1.46 (+0.49%)

As of 05/22/2026 07:29 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen NASDAQ:BIIB

$193.76 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$193.50 -0.26 (-0.13%)

As of 05/22/2026 07:14 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Regeneron Pharmaceuticals NASDAQ:REGN

$638.88 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$634.44 -4.44 (-0.69%)

As of 05/22/2026 07:55 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Vertex Pharmaceuticals NASDAQ:VRTX

$434.52 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$433.41 -1.11 (-0.26%)

As of 05/22/2026 07:32 PM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALNY, VRTX, REGN, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALNY, VRTX, REGN, and BIIB Earnings

Compare Dividends

Latest ALNY, VRTX, REGN, and BIIB Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALNY, VRTX, REGN, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ALNY, VRTX, REGN, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Biogen NASDAQ:BIIB

Regeneron Pharmaceuticals NASDAQ:REGN

Vertex Pharmaceuticals NASDAQ:VRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools